Influenza virus vectors and uses therefor
Inventors
LeFebvre, Matthew Frederick • Hatta, Yasuko • Bilsel, Pamuk • Moser, Michael J.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11980662-B2
Publication Date
2024-05-14
Expiration Date
Abstract
Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. The mutant viruses disclosed herein including a mutant M2 sequence are also useful to deliver antigens to a subject, e.g., to induce an immune response to the antigen. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.
Core Innovation
The invention relates to an immunogenic composition comprising the nucleic acid sequence of SEQ ID NO:35, wherein SEQ ID NO:35 further comprises a nucleic acid sequence encoding one or more antigens. The nucleic acid is used to generate immunogenicity by encoding foreign antigen and/or pathogen-derived antigens and/or tumor-derived antigens.
In the disclosed embodiments, SEQ ID NO:35 further comprises or is combined with a nucleic acid sequence of SEQ ID NO:36. The one or more antigens are defined as amino-acid sequences derived from pathogens or tumors, with pathogen types including virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.
The disclosure also includes recombinant influenza-virus based systems in which the nucleic acid sequence is present in a recombinant influenza virus, enabling propagation in a host cell and isolation of progeny virus particles. Vaccine preparation and administration are supported by using the recombinant virus-containing sequence to produce progeny particles and formulating them for administration as a vaccine, with the broader disclosure emphasizing mutant influenza viral vectors and M2 mutants as immunogenic components.
Claims Coverage
The independent claim covers an immunogenic composition defined by the nucleic acid sequence of SEQ ID NO:35 and the presence of antigen-encoding nucleic acid within SEQ ID NO:35. The inventive features across dependent claims refine the antigen sources and extend coverage to recombinant influenza-virus propagation and vaccine preparation, for a total of one independent claim with multiple refinement paths.
Nucleic acid sequence encoding antigens in SEQ ID NO:35
An immunogenic composition comprising the nucleic acid sequence of SEQ ID NO:35, wherein SEQ ID NO:35 further comprises a nucleic acid sequence encoding one or more antigens.
Additional nucleic acid sequence SEQ ID NO:36
The immunogenic composition of claim 1 further comprises part or all of SEQ ID NO:36.
Pathogen- or tumor-derived antigen amino-acid sequences
The one or more antigens comprise an amino acid sequence derived from a pathogen or a tumor.
Specified pathogen categories for antigen derivation
The pathogen comprises a virus, bacteria, fungus, protozoan, multi-cellular parasite, or prion.
Recombinant influenza virus propagation using the claimed nucleic acid
A method of propagating a recombinant influenza virus by contacting a host cell with a recombinant influenza virus containing the nucleic acid sequence of claim 1, incubating for a sufficient time under conditions suitable for viral replication, and isolating progeny virus particles.
Vaccine preparation using bioreactor-propagated progeny virus particles
A method of preparing a vaccine by placing a host cell in a bioreactor, contacting it with a recombinant virus containing the nucleic acid sequence of claim 1, incubating under conditions suitable for viral propagation, isolating progeny virus particles, and formulating the particles for administration as a vaccine.
Overall, claim coverage centers on immunogenic compositions defined by SEQ ID NO:35 encoding one or more antigens, optional inclusion of SEQ ID NO:36, and antigen definitions as pathogen- or tumor-derived amino-acid sequences with specified pathogen categories. Additional coverage extends to methods using the same nucleic acid sequence within recombinant influenza viruses for propagation in host cells and bioreactor-based vaccine preparation through isolation and formulation of progeny virus particles.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?